Name: A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas (Video) | JoVE Journal
Uploaded: 2025-05-09T12:20:00.000+00:00
Duration: 6 min 27 s
Description: Learn a non-enzymatic explant protocol for long-term culture of IDH1-mutant diffuse low-grade gliomas. This method maintains tumor cell plasticity and supports neuroscience and oncology research.

ai_agent_IP

ai_agent

maintenance

instantTrialDurationMinutes

isBiopharma

enableNewMyJoveSectionDesign

educationFeatures

seoMetaApi

ai_copilot_institution_blacklist

ai_chat_institution_blacklist

freeAccessWindow

ssoRoleCapture

scheduledMaintenanceBanner

joveLabsFeatures

disable_autoplay_for_bots

extended_trial_duration

5 minutes

The tumor fragments used here are part of the NEUROLOGY collection of fresh tissue samples maintained by the Biological Resource Center at Montpellier University Hospital (CRB@chu-montpellier.fr). This research was conducted under the project titled &#34;Gliomacult: Characterization and Primary Cultures of Low-Grade Gliomas,&#34; led by Prof. J. P. Hugnot (Project No. RECH/P722/1-5). This work was supported by La ligue contre le cancer, ARC (Association for Cancer Research), ARTC, ARTC SUD, Les Etoiles dans la mer, EMBALL&#39;ISO, R&#233;gion Occitanie, INCA. K.A.C is supported by the National Council of Humanities Science and Technology (CONAHCYT), Mexico, and the Association for Brain Tumor Research (ARTC), France.

The tumor fragments utilized in this protocol were obtained from a well-characterized and ethically approved collection, with patient consent. This research was conducted under the project titled Gliomacult: Characterization and Primary Cultures of Low-Grade Gliomas (Project No. RECH/P722/1-5) and was approved by the tumor biobank's scientific council on August 28, 2023.
1. Preparation of culture plates
NOTE: Perform these steps under a sterile tissue culture laminar flow hood.
<ol>
	<li>At least 1 h before culture, prepare poly-D-lysine (PDL) and laminin-coated 24 well plates.
	<ol>
		<li>Dilute 10 mg of PDL powder in 100 mL of borate buffer (pH 8.4) for a final concentration of 100 µg/mL. Once dissolved, filter the solution (0.22 µm) for sterility. PDL is ready to use; prepare 3 mL aliquots and store them at -20 °C.</li>
		<li>Thaw the 1-2 mg/mL laminin tube at 4 °C to avoid gel formation. Prepare 50 µL aliquots and store them at -20 °C. 
		NOTE: Repeating thawing and freezing should be avoided.</li>
		<li>Plate coating
		<ol>
			<li>Optional step: place sterile coverslips Ø, 13 mm, suitable for cell culture dishes, in a 24-well plate, one coverslip per well. 
			NOTE: This step is for further immunostaining of glioma explants.</li>
			<li>For the coating of the wells, mix the 3 mL of the PDL solution in 9 mL of 1x PBS and add 50 µL of laminin. Add 500 µL of this solution to each well for a 1-2 µg/cm² coating concentration. Incubate the coated plates at room temperature, preferably with slow rocking (15 RPM), for at least 1 h.</li>
			<li>Immediately before the culture, remove the PDL-laminin solution and rinse twice with sterile 1x PBS. 
			NOTE: Do not let the wells dry out.</li>
		</ol>
		</li>
	</ol>
	</li>
</ol>
2. Media
<ol>
	<li>Culture IDH1-mutant explants in a defined medium comprising DMEM/F12 supplemented with L-glutamine, along with a serum-replacement blend consisting of N2 and B27 without Vitamin A. Use antibiotics, including ciprofloxacin, gentamicin, and fungin, to prevent bacterial and fungal contamination. Additionally, incorporate growth factors heparin, EGF, and FGF2 into the medium, filter it (0.2 µm), and store it for up to 2 weeks at 4 °C. 
	NOTE: For details on media ingredients and preparation, refer to Table 1 and the Table of Materials.</li>
</ol>
3. Explant preparation
<ol>
	<li>Before sample processing, prepare the workspace and sterile tools as depicted in Figure 1A. Sanitize a cool pack by spraying it with 70% ethanol. Sterilize scissors and forceps by immersing them in 70% ethanol and rinsing them with PBS.</li>
	<li>Promptly transfer the tumor resection for culture on ice, ideally within 2 h post surgical extraction (Figure 1B). 
	NOTE: The tumor sample should have a minimum diameter of 9-10 mm to ensure better results. The tissue is transported without culture medium as this method is preferred for histological purposes. The absence of liquid prevents ice crystal formation during flash freezing, thereby preserving tissue integrity for subsequent histological examination if necessary.</li>
	<li>Place the culture dish with the tumor specimen over the cool pack and gently rinse it with 1X PBS to remove excess blood.</li>
	<li>The resected tumor often exhibits significant size and heterogeneity, comprising tumor mass, infiltrated tissue, and non-tumoral components (Figure 1C). Select portions displaying a gray color with a soft or jelly-like texture for tumor cell isolation, as they tend to contain more tumor cells. Conversely, avoid hard and white regions as they may contain fewer tumor cells suitable for culture (Figure 1D), as well as blackened areas, as they are likely a result of electrocautery and may not provide reliable results for analysis.</li>
	<li>Transfer the selected samples into a 1.5 mL microtube or cryovial for mincing. Add 1 mL of sterile media to the 1.5 mL microtube or cryovial and chop the sample with the sterile scissors until small pieces (1-2 mm3) are obtained. 
	NOTE: Approximately 1-2 min of chopping is necessary to obtain tiny fragments, typically 1-2 mm3 in size (Figure 1E).</li>
	<li>With sterile scissors, carefully trim the end of a blue 1,000 µL pipette tip to create a wide opening, roughly 3-4 mm in diameter. Employing this modified tip, pipette 50-200 µL of the minced tissue fragments and distribute them evenly across each well. Because the smaller pieces tend to settle rapidly, gently re-homogenize the suspension in each well to ensure uniform distribution. 
	​NOTE: Avoid overcrowding and maintain a balance by not introducing an excessive number of fragments into each well (Figure 1F).</li>
	<li>Incubate the tumor fragments at 37°C in a 5% CO2 incubator with 100% humidity. Change the media every day if the tumor's metabolic activity (indicated by rapid yellowing of the media) and the number of fragments in each well requires it. During media changes, exercise care by delicately aspirating the media using a pipette equipped with a 200 µL tip, ensuring to avoid disturbing any adhering tumor fragments.</li>
</ol>
<img alt="Tumor tissue preparation process; equipment setup; tissue samples; centrifuge results; analysis chart." class="xfigimg" src="/files/ftp_upload/67260/67260fig01.jpg" data-altupdatedat="1788304762000" data-alt="Figure 1"> 
Figure 1: Tumor explant culture procedure. A diffuse low-grade glioma resection was obtained from a 44-year-old patient diagnosed with a grade II astrocytoma according to the WHO 2021 classification. The tumor exhibited an IDH1 mutation (Exon 4 c.395 G&gt;A, p.Arg132His) and a TP53 mutation (Exon 8 c.843_844delinsGT, p.Asp281_Arg282delinsGluHis), along with the absence of ATRX staining. No mutations were detected in the Ets/TCF binding sites (C250T and C228T) of the TERT gene. (A) The working surface comprises a cool pack, providing an environment that minimizes sample degradation and maintains the viability of biological components. These precautions are important for preserving the quality and integrity of the tissue. (B) Transport of the sample from the hospital to the lab should be done on ice. (C) Tumor resection fragment. Arrows show the most suitable parts for culture. (D) Dissection of the tumor is performed to select the most relevant part to be minced. In our experience, white matter is generally less likely to generate successful explants. (E) Tumor fragments of approximately 1-2 mm³ of diameter in a 15 mL tube after being mechanically minced with scissors. (F) The number of tumor pieces required for the proper seeding is shown for wells on a 24-well plate. <a href="https://www.jove.com/files/ftp_upload/67260/67260fig01large.jpg" target="_blank">Please click here to view a larger version of this figure.</a>
4. Minced tumor cryopreservation and thawing
NOTE: Cryopreservation ensures backup in case of contamination and loss of explant cultures or to process the tumor samples later.
<ol>
	<li>Cryopreservation: Prepare the freezing medium (20% v/v DMSO solution) by adding 2 mL of DMSO to 8 mL of cell culture medium.</li>
	<li>Combine 1 volume of the minced tumor suspension with an equal volume of the 20% DMSO freezing medium to achieve a final concentration of 10% DMSO. Carefully pipette the mixture up and down to ensure thorough blending, then dispense approximately 1 mL into cryovials.</li>
	<li>Rapidly transfer the cryovials into a cryogenic container for gradual temperature reduction, followed by overnight incubation at -80 °C before final storage in liquid nitrogen. 
	NOTE: This step must be performed immediately after the cells are placed in the freezing medium, as certain cryoprotectants, like DMSO, can be harmful if the cells are exposed to them at room temperature for longer than necessary.</li>
	<li>Thawing: Remove the cryovials from the liquid nitrogen and immediately place them in a 37 °C water bath until around 80% of the cells have thawed.</li>
	<li>To remove the DMSO, quickly pipette the suspension into a 15 mL centrifuge tube containing 5 mL of prewarmed 1x PBS and centrifuge at 300 × g for 5 min.</li>
	<li>Remove the supernatant and repeat the wash with 1X PBS followed by centrifugation (step 4.5). Aspirate the supernatant, taking care not to disturb the pellet, and add the appropriate amount of medium to transfer into a precoated PDL-Laminin 24-well plate and place in the incubator.</li>
	<li>After 24 h, verify that the cells have attached. After a few days, remove non-adherent fragments by replacing the culture media.</li>
</ol>
5. Passage of the culture
NOTE: Once established, explants can be used for videomicroscopy or immunostaining. Alternatively, if tumor cells have migrated out of the explant and appear healthy, the explant can be passaged through enzymatic dissociation and reseeded in wells for further experimentation. However, it is important to note that this protocol is not designed for repeated passaging. Typically, only a single passage can be attempted before the tumor cells become senescent or die. Not all explant cultures will result in successful passage.
<ol>
	<li>To passage, remove old media, rinse with 1X PBS, and add (125 µL) 0.05% trypsin-EDTA to the wells and incubate for 3-4 min at 37 °C, followed by the addition of 6.5 µL of Trypsin Inhibitor, 12 µL of 20 mM CaCl2 (final dilution to 2mM), and 1 µL of DNAse I. 
	NOTE: The incubation time needed for dissociation may vary depending on the culture. It is important to check whether the cells are detached after at least 3 min. Typically, the explant may not be fully dissociated into a single-cell suspension, and small clusters are often retained, which can generate new explant cultures.</li>
	<li>With a p1000 set on 500-600 µL, flush gently to disaggregate explants. Avoid bubble formation.</li>
	<li>Add 5 mL of 1x PBS and centrifuge for 5 min at 300 × g. Aspirate the supernatant, resuspend the pellet in fresh prewarmed medium, and count for seeding.</li>
	<li>Identify cultures with the potential to generate cell lines by observing dividing cells under a phase-contrast microscope. These dividing cells typically have a rounded morphology and visible chromosomes, as shown in Figure 2A.</li>
</ol>

<ol><li>Dasgupta, P., Balasubramanyian, V., De Groot, J. F., Majd, N. K. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Preclinical+models+of+low-grade+gliomas%5BTitle%5D)+AND+%22Cancers+%28Basel%29%22%5BJournal%5D)">Preclinical models of low-grade gliomas.</a> Cancers (Basel). 15 (3), 596(2023).</li>
<li>Tirosh, I., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Single-cell+RNA-seq+supports+a+developmental+hierarchy+in+human+oligodendroglioma%5BTitle%5D)+AND+%22Nature%22%5BJournal%5D)">Single-cell RNA-seq supports a developmental hierarchy in human oligodendroglioma.</a> Nature. 539 (7628), 309-313 (2016).</li>
<li>Jooma, R., Waqas, M., Khan, I. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Diffuse+low-grade+glioma+-+changing+concepts+in+diagnosis+and+management%3A+A+review%5BTitle%5D)+AND+%22Asian+J+Neurosurg%22%5BJournal%5D)">Diffuse low-grade glioma - changing concepts in diagnosis and management: A review.</a> Asian J Neurosurg. 14 (2), 356-363 (2019).</li>
<li>Louis, D. N. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Molecular+pathology+of+malignant+gliomas%5BTitle%5D)+AND+%22Annu+Rev+Pathol%22%5BJournal%5D)">Molecular pathology of malignant gliomas.</a> Annu Rev Pathol. 1, 97-117 (2006).</li>
<li>Adenis, L., Plaszczynski, S., Grammaticos, B., Pallud, J., Badoual, M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((The+effect+of+radiotherapy+on+diffuse+low-grade+gliomas+evolution%3A+Confronting+theory+with+clinical+data%5BTitle%5D)+AND+%22J+Pers+Med%22%5BJournal%5D)">The effect of radiotherapy on diffuse low-grade gliomas evolution: Confronting theory with clinical data.</a> J Pers Med. 11 (8), 818(2021).</li>
<li>Pirozzi, C. J., Yan, H. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((The+implications+of+idh+mutations+for+cancer+development+and+therapy%5BTitle%5D)+AND+%22Nat+Rev+Clin+Oncol%22%5BJournal%5D)">The implications of idh mutations for cancer development and therapy.</a> Nat Rev Clin Oncol. 18 (10), 645-661 (2021).</li>
<li>Van Den Bent, M. J., Smits, M., Kros, J. M., Chang, S. M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Diffuse+infiltrating+oligodendroglioma+and+astrocytoma%5BTitle%5D)+AND+%22J+Clin+Oncol%22%5BJournal%5D)">Diffuse infiltrating oligodendroglioma and astrocytoma.</a> J Clin Oncol. 35 (21), 2394-2401 (2017).</li>
<li>Suva, M. L., Tirosh, I. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((The+glioma+stem+cell+model+in+the+era+of+single-cell+genomics%5BTitle%5D)+AND+%22Cancer+Cell%22%5BJournal%5D)">The glioma stem cell model in the era of single-cell genomics.</a> Cancer Cell. 37 (5), 630-636 (2020).</li>
<li>Augustus, M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Identification+of+CRYAB%2B+KCNN3%2B+SOX9%2B+astrocyte-like+and+EGFR%2B+PDGFRA%2B+OLIG1%2B+oligodendrocyte-like+tumoral+cells+in+diffuse+idh1-mutant+gliomas+and+implication+of+NOTCH1+signalling+in+their+genesis%5BTitle%5D)+AND+%22Cancers+%28Basel%29%22%5BJournal%5D)">Identification of CRYAB+ KCNN3+ SOX9+ astrocyte-like and EGFR+ PDGFRA+ OLIG1+ oligodendrocyte-like tumoral cells in diffuse idh1-mutant gliomas and implication of NOTCH1 signalling in their genesis.</a> Cancers (Basel). 13 (9), 2107(2021).</li>
<li>Hubert, C. G., Rich, J. N. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Patient-derived+explants+as+tumor+models%5BTitle%5D)+AND+%22Cancer+Cell%22%5BJournal%5D)">Patient-derived explants as tumor models.</a> Cancer Cell. 40 (4), 348-350 (2022).</li>
<li>Abdullah, K. G., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Establishment+of+patient-derived+organoid+models+of+lower-grade+glioma%5BTitle%5D)+AND+%22Neuro+Oncol%22%5BJournal%5D)">Establishment of patient-derived organoid models of lower-grade glioma.</a> Neuro Oncol. 24 (4), 612-623 (2022).</li>
<li>Yuzhakova, D. V., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Development+of+a+3d+tumor+spheroid+model+from+the+patient%27s+glioblastoma+cells+and+its+study+by+metabolic+fluorescence+lifetime+imaging%5BTitle%5D)+AND+%22Sovrem+Tekhnologii+Med%22%5BJournal%5D)">Development of a 3d tumor spheroid model from the patient's glioblastoma cells and its study by metabolic fluorescence lifetime imaging.</a> Sovrem Tekhnologii Med. 15 (2), 28-38 (2023).</li>
<li>Kloosterman, D., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Morphology+of+microglia+across+contexts+of+health+and+disease%5BTitle%5D)+AND+%22Cell%22%5BJournal%5D)">Morphology of microglia across contexts of health and disease.</a> Cell. 187, 5336-5356.e30 (2024).</li>
<li>Thomas, D. L. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((2021+updates+to+the+World+Health+Organization+classification+of+adult-type+and+pediatric-type+diffuse+gliomas%3A+A+clinical+practice+review%5BTitle%5D)+AND+%22Chin+Clin+Oncol%22%5BJournal%5D)">2021 updates to the World Health Organization classification of adult-type and pediatric-type diffuse gliomas: A clinical practice review.</a> Chin Clin Oncol. 12 (1), 7(2023).</li>
<li>Azar, S., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Cellular+and+molecular+characterization+of+IDH1-mutated+diffuse+low+grade+gliomas+reveals+tumor+heterogeneity+and+absence+of+EGFR%2FPDGFRalpha+activation%5BTitle%5D)+AND+%22Glia%22%5BJournal%5D)">Cellular and molecular characterization of IDH1-mutated diffuse low grade gliomas reveals tumor heterogeneity and absence of EGFR/PDGFRalpha activation.</a> Glia. 66 (2), 239-255 (2018).</li>
<li>Bhaduri, A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Outer+radial+glia-like+cancer+stem+cells+contribute+to+heterogeneity+of+glioblastoma%5BTitle%5D)+AND+%22Cell+Stem+Cell%22%5BJournal%5D)">Outer radial glia-like cancer stem cells contribute to heterogeneity of glioblastoma.</a> Cell Stem Cell. 26 (1), 48-63.e6 (2020).</li>
</ol>

The authors have no conflicts of interest to declare.

Developing in vitro and preclinical models for IDH1-mutant low-grade gliomas is particularly challenging due to the slow growth of these tumors and the complexity of replicating the extensive genomic and epigenomic alterations caused by the IDH mutation. Moreover, these infiltrative tumor cells actively interact with surrounding cells, including immune, endothelial, glial, and neuronal cells, potentially relying on them for survival. This complex interplay is difficult to replicate in a laboratory setting.
<p class="...

Diffuse gliomas are the most frequent primary brain tumors. These tumors are currently incurable despite very intense treatment (surgery, radio, and chemotherapy)1. Increasing evidence supports the hypothesis that gliomagenesis originates from adult stem or glial progenitor cells resident in the brain2. Although glioblastomas represent the most aggressive type, diffuse low-grade gliomas (DLGG, grade 2 tumors)&#160;are also prevalent (15% of diffuse gliomas)1,3. DLGGs grow slowly and migrate along white matter tracts, a hallmark of this &#39;diffuse&#39; neoplasm4. These DLGG very often recur despite treatment, ultimately progressing to high-grade malignancies (grades 3 and 4)5.
DLGG are characterized by a missense mutation in the isocitrate dehydrogenase 1 or 2 gene (IDH1 or IDH2), resulting in the aberrant production of the oncometabolite 2-hydroxyglutarate (2HG). This disrupts cell differentiation through epigenetic dysregulations6. IDH1-mutant gliomas are further classified into subtypes: astrocytomas typically have mutations in ATRX and P53, while oligodendrogliomas are characterized by 1p19q deletions7. These tumors exhibit a heterogeneity of tumoral cells. Single-cell RNA sequencing and immunocharacterization have revealed a diverse population of tumor cells, displaying stem-cell-like, astrocyte-like, and oligodendrocyte-like phenotypes within these tumors8,9.
In contrast to glioblastoma, which benefits from readily available, long-term cultures and cell lines, there exists a notable scarcity of cellular tools tailored for investigating IDH1-mutant tumors1. This presents a significant obstacle to advancing therapeutic development and deepening our understanding of IDH1-mutant gliomagenesis and disease progression. Traditional serum-grown cell lines, while long-utilized, inadequately replicate original tumors, displaying altered transcriptional profiles. Alternatively, serum-free culture conditions, whether in 2D or 3D tumoroid models, more effectively preserve the transcriptional profiles of tumor cells and their in vivo phenotypes, such as invasion into normal brain tissue10,11.
In addition, short-term cell cultures derived from a patient&#39;s surgical specimen preserve the molecular profile and cellular diversity of the tumor, thereby better representing the biological traits of tumors compared to cell lines12. Herein, we introduce a straightforward non-enzymatic method for culturing IDH1-mutant diffuse low-grade gliomas culture as explants derived from fresh or frozen patient resections, aiming to address the need for improved in vitro models for glioma research and therapeutic development. They also offer the potential to derive IDH1-mutant cell lines.

<table><tbody><tr><td>Anti-ASCL1</td><td>BD Pharmingen&amp;trade;</td><td>556604</td><td>Dilution 1:500</td></tr><tr><td>Anti-ATRX</td><td>Sigma-Aldrich</td><td>HPA001906</td><td>Dilution 1:100</td></tr><tr><td>Anti-CD68</td><td>Agilent</td><td>M081401-2</td><td>Dilution 1:500</td></tr><tr><td>Anti-GFAP</td><td>Aves Labs</td><td>AB_2313547</td><td>Dilution 1:500</td></tr><tr><td>Anti-IBA1</td><td>Fujifilm Wako Antibodies</td><td>019-19741</td><td>Dilituion 1:1000</td></tr><tr><td>Anti-IDH1 (R132H) mouse Monoclonal Antibody</td><td>Dianova</td><td>DIA-H09</td><td></td></tr><tr><td>Anti-Ki67</td><td>BD Pharmingen&amp;trade;</td><td>556003</td><td>Dilituion 1:1000</td></tr><tr><td>Anti-OLIG1</td><td>R&amp;amp;D Systems&amp;reg;</td><td>AF2417</td><td>Dulituion 1:300</td></tr><tr><td>Anti-OLIG2</td><td>Sigma-Aldrich</td><td>MABN50</td><td>Dilution 1:250</td></tr><tr><td>Anti-SOX9</td><td>Abcam&amp;reg;</td><td>EPR14335-78</td><td>Dilution 1:100</td></tr><tr><td>B-27 Supplement (50x), minus vitamin A</td><td>Thermo Fisher Scientific</td><td>12587010</td><td></td></tr><tr><td>Bovine Serum Albumin (BSA)</td><td>CiteAb</td><td>A-421-100</td><td></td></tr><tr><td>Ciprofloxacin HCl</td><td>Sigma-Aldrich</td><td>PHR1044-1G</td><td></td></tr><tr><td>CoolCell</td><td>Corning&amp;reg;</td><td>432000</td><td>Cell Freezing Container, for 12 x 1 mL or 2 mL Cryogenic Vials</td></tr><tr><td>Cover slip &amp;Oslash;, 13 mm</td><td>Karl Hecht&amp;trade; Assistent&amp;trade;</td><td>328017</td><td></td></tr><tr><td>Dimethyl Sulfoxide (DMSO)</td><td>Sigma-Aldrich</td><td>D8418</td><td></td></tr><tr><td>DMEM/F-12, no glutamine</td><td>Thermo Fisher Scientific</td><td>21331020</td><td></td></tr><tr><td>DNAse I</td><td>Sigma-Aldrich</td><td>10104159001</td><td></td></tr><tr><td>Dulbecco&amp;prime;s Phosphate Buffered Saline (PBS) 1x</td><td>Sigma-Aldrich</td><td>D8537</td><td></td></tr><tr><td>Falcon 100 mm TC-treated Cell Culture Dish</td><td>Corning&amp;reg;</td><td>353003</td><td></td></tr><tr><td>Falcon 24-well Clear Flat Bottom</td><td>Corning&amp;reg;</td><td>353047</td><td>TC-treated Multiwell Cell Culture Plate, with Lid, Sterile&amp;nbsp;</td></tr><tr><td>Fungin</td><td>InvivoGen</td><td>ant-fn-1</td><td></td></tr><tr><td>Gentamicin</td><td>Thermo Fisher Scientific</td><td>15750-037</td><td></td></tr><tr><td>Heparin</td><td>Sigma-Aldrich</td><td>H3149-100KU</td><td></td></tr><tr><td>HEPES</td><td>Sigma-Aldrich</td><td>H-3375</td><td></td></tr><tr><td>Human EGF</td><td>PeproTech</td><td>AF-100-15-1MG</td><td></td></tr><tr><td>Human FGF-basic</td><td>PeproTech</td><td>100-18B-1MG</td><td></td></tr><tr><td>Laminin</td><td>Sigma-Aldrich</td><td>L2020</td><td></td></tr><tr><td>L-Glutamine</td><td>Thermo Fisher Scientific</td><td>25030-024</td><td></td></tr><tr><td>N-2 Supplement (100x )</td><td>Thermo Fisher Scientific</td><td>17502-048</td><td></td></tr><tr><td>PDL</td><td>Sigma-Aldrich</td><td>P7886</td><td></td></tr><tr><td>Serum acrodisc 37 mm syringe filter with GF/0.2 &amp;micro;m Supor</td><td>PALL Corporation</td><td>4525</td><td></td></tr><tr><td>Trypsin Inhibitor</td><td>Thermo Fisher Scientific</td><td>17075-029</td><td></td></tr><tr><td>Trypsin-EDTA (0.05%), phenol red</td><td>Thermo Fisher Scientific</td><td>25300054</td><td></td></tr><tr><td>Zeiss Z1 Apotome 3 microscope</td><td>Zeiss</td><td></td><td>straight widefield epifluorescence microscope</td></tr></tbody></table>

a protocol for explant cultures of idh1-mutant diffuse low-grade gliomas

A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas

Diffuse gliomas, the most prevalent primary brain tumors, are categorized into low and high grades based on histopathological criteria and genetic mutations. Diffuse low-grade gliomas constitute a subset, predominantly afflicting young adults and predisposing to high-grade gliomas. There are two main types of diffuse low-grade gliomas: astrocytomas and oligodendrogliomas, each defined by distinct genetic and histological features. These tumors characteristically exhibit a mutated variant of the metabolic enzyme IDH1, disrupting cellular differentiation. They are heterogeneous, comprising both proliferative stem cells and more differentiated, quiescent glial cells. 
Patient-specific, in vitro tumor models hold significant potential for unraveling oncogenic mechanisms and tailoring drug selection for personalized therapy. However, the absence of reliable in vitro models specifically for IDH1-mutant low-grade gliomas has hindered fundamental and translational research. Here, we present a simple method for culturing IDH1-mutant tumors as explants in defined media without needing enzymatic dissociation. These explants can be sustained for extended periods, maintaining IDH1-mutant protein expression as well as markers for oligodendrocyte progenitor cells such as ASCL1 (MASH1), OLIG1, and OLIG2 and for astrocytes (GFAP, SOX9). They can also be established from frozen tumors in DMSO. These cultures can serve as a valuable platform for drug screening, videomicroscopy, and gene studies, thus facilitating advancements in understanding and treating these challenging tumors. They also offer the potential to derive IDH1-mutant cell lines.

After a few days, some tumor fragments will adhere to the well surfaces, initiating the outgrowth of cells from the explants. The time between the initial plating and the appearance of tumoral growing cells is different from sample to sample. The initial cultures often contain substantial cellular debris, making it difficult to assess the presence of viable cells. Consequently, the culture should be maintained for a minimum of 4 weeks. Once the cells start to grow, elongated cells with a bipolar or multipolar appearance ...

IDH1-mutant diffuse low-grade gliomas are rare tumors that are difficult to culture. We introduce a simple, non-enzymatic explant method that preserves IDH1-mutant protein expression and sustains cultures for months. Importantly, this technique works with cryopreserved tumors, offering a valuable resource for glioma research.

Diffuse gliomas, the most prevalent primary brain tumors, are categorized into low and high grades based on histopathological criteria and genetic ...

a-protocol-for-explant-cultures-idh1-mutant-diffuse-low-grade

Research

JoVE Journal

Cancer Research

This video demonstrates the process of isolating and culturing glial progenitor cells from diffuse intrinsic pontine glioma, or DIPG-affected brainstem tissue. Glial cells isolated from tumor tissue via an enzymatic digestion are cultured in a neurobasal medium, which promotes their growth and the development of free-floating neurospheres.

Isolating and Culturing Cells from Diffuse Intrinsic Pontine Glioma

Malignant gliomas constitute a heterogeneous group of highly infiltrative glial neoplasms with distinct clinical and molecular features. Primary orthotopic xenografts recapitulate the histopathological and molecular features of malignant glioma subtypes in preclinical animal models.

Primary Orthotopic Glioma Xenografts Recapitulate Infiltrative Growth and Isocitrate Dehydrogenase I Mutation

Protocol for propagation of dissociated high grade glioma surgical specimens in serum-free neurosphere medium to select for cells with cancer stem cell phenotype. For specimens that fail to grow as neurospheres, an alternative protocol is suggested. A paraffin embedding technique for maintaining the 3D neurosphere architecture for immunocytochemistry is described.

Optimization of High Grade Glioma Cell Culture from Surgical Specimens for Use in  Clinically Relevant Animal Models and 3D Immunochemistry

Presented here is a straightforward method for the isolation and flow cytometric analysis of glioma-infiltrating peripheral blood mononuclear cells that yields time-dependent quantitative data on the number and activation status of immune cells entering the early brain tumor microenvironment.

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

This protocol describes a method for the rapid processing of post-mortem diffuse intrinsic pontine glioma samples for the establishment of patient-derived cell culture models or direct characterization of tumor and microenvironmental cells.

A Protocol for Rapid Post-mortem Cell Culture of Diffuse Intrinsic Pontine Glioma (DIPG)

This study introduces and describes protocols to derive two specific human neural organoids as a relevant and accurate model for studying 1) human glioblastoma development within human neural organoids exclusively in humans and 2) neuron dopaminergic differentiation generating a three-dimensional organoid.

Human Neural Organoids for Studying Brain Cancer and Neurodegenerative Diseases

Here we present an ex-vivo mixed monolayer culture system for the study of human glioma cell (hGC) migration in real-time. This model provides the ability to observe interactions between hGCs and both myelinated and non-myelinated axons within a compartmentalized chamber.

Real-Time Monitoring of Human Glioma Cell Migration on Dorsal Root Ganglion Axon-Oligodendrocyte Co-Cultures

This study presents a protocol of live-3D-cell immunocytochemistry applied to a pediatric diffuse midline glioma cell line, useful to study in real-time the expression of proteins on the plasma membrane during dynamic processes like 3D cell invasion and migration.

Live-3D-Cell Immunocytochemistry Assays of Pediatric Diffuse Midline Glioma

Proteomic dysregulation plays an important role in the spread of diffusely infiltrating gliomas, but several relevant proteins remain unidentified. Digital spatial processing (DSP) offers an efficient, high-throughput approach for characterizing the differential expression of candidate proteins that may contribute to the invasion and migration of infiltrative gliomas.

Digital Spatial Profiling for Characterization of the Microenvironment in Adult-Type Diffusely Infiltrating Glioma

Here, we describe a method of generating glioblastoma (GBM) organoids from primary patient specimens or patient-derived cell cultures and maintaining them to maturity. These GBM organoids contain phenotypically diverse cell populations and recreate tumor microenvironments ex vivo.

Maintaining Human Glioblastoma Cellular Diversity Ex vivo using Three-Dimensional Organoid Culture

Learn a non-enzymatic explant protocol for long-term culture of IDH1-mutant diffuse low-grade gliomas. This method maintains tumor cell plasticity and supports neuroscience and oncology research.

A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas

Explore More Videos